New Pfizer Oncology Data Across Numerous Cancer Types to be,Presented at ASCO ( patientswith advanced refractory thyr...)

New Pfizer Oncology Data Across Numerous Cancer Types to be,Presented at ASCO

patients with advanced refractory thyroid cancer.

-- Overall survival in patients with advanced pancreatic cancer treated with axitinib in combination with gemcitabine or gemcitabine alone.

-- Single-agent efficacy and safety of axitinib in advanced, refractory NSCLC.

Signal Transduction

-- A phase II trial evaluated the safety and efficacy of the investigational compound CP-751,871 in combination with paclitaxel and carboplatin as first-line treatment for NSCLC and standard therapy (paclitaxel and carboplatin alone).

Immuno-Oncology

-- Four different presentations evaluating CP-675,206 in metastatic melanoma and one presentation evaluating CP-675,206 in refractory CRC will be unveiled at ASCO.

-- Results from a multi-dose phase I/II clinical trial that evaluated safety, response, and survival in patients with advanced metastatic melanoma treated with CP-675,206 will be presented in an oral presentation. Two different dosing regimens were evaluated in the phase II arm, providing information on the selected dosing regimen in the phase III program.

Pfizer also announced the expansion of the clinical trial program evaluating the efficacy and safety of sunitinib malate in the treatment of breast cancer. Pfizer has initiated three additional phase III trials to further evaluate sunitinib malate in metastatic breast cancer. This robust research program now includes a total of four phase III and two phase II trials and will include more than 2,600 patients worldwide.

Phase III programs evaluating sunitinib malate in CRC, NSCLC and liver cancer will also be initiated. Professionals interested in learning more about sunitinib malate trials in various cancers can access www.suntrials.com - a clinical resource for healthcare providers.

"SUTENT has proven to be an important therapy in the treatment of advanced kidney cancer and imatinib-resistant gastrointestinal stromal tumor, for which it is currently appr
'"/>

Page: 1 2 3 4 5
Related medicine technology :

1. New Data Show Pfizers Axitinib Prolonged Overall Survival in Advanced Pancreatic Cancer When Combined with Standard of Care Chemotherapy
2. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
3. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
4. Gloucester Pharmaceuticals Reports Positive Interim Phase II Data on Romidepsin for T-Cell Lymphomas at the 2007 American Society of Clinical Oncology Annual Meeting
5. MGI Pharma Summarizes Data Presented at the 2007 American Society of Clinical Oncology (ASCO) Annual Meeting
6. MGI Pharma, Inc. Summarizes Data Presented at the 2007 American Society of Clinical Oncology (ASCO) Annual Meeting
7. Hana Biosciences Presents Data On Two Programs At the American Society of Clinical Oncology Annual Meeting
8. Access and Somanta Announce Data to be Presented on Angiolix at ASCO Oncology Conference
9. Pharmion to Present Clinical Data on Commercial and Pipeline Products at 2007 American Society of Clinical Oncology (ASCO) Meeting
10. CytImmune Presents Positive CYT-6019 Data During the American Society of Clinical Oncology Annual Meeting in Chicago
11. Clinical Data on Eisais Oncology Pipeline to be Presented at ASCO Annual Meeting

Post Your Comments:

( patientswith advanced refractory thyr...)New Pfizer Oncology Data Across Numerous Cancer Types to be,Presented at ASCO,Health